...Stefan E. Matthiasson; Bengt Lindblad; David Bergqvist In a randomized, blind study the antithrombotic efficacy of dermatan sulphate (DS), recombinant hirudin (r-hirudin) and four commercially available low molecular weight heparins (LMWHs) was investigated after intravenous administration...

... have demonstrated that low molecular weight heparins, that have improved pharmacologic and pharmacokinetic properties over standard heparin, are effective and safe in the treatment of deep vein thrombosis. Two large randomized clinical trials have shown the feasibility of the outpatient treatment...

... phylaxis, low molecular weight heparin, enoxaparin, hip arthroplasty. ABSTRACT This review deals with the problem of delayed thrombosis and thereby the potential need of prolonged prophylaxis. The risk of late thrombosis and pulmonary embolism is discussed from pathogenetic factors and data on frequencies...

... approach of unfractionated heparin administered by continuous intravenous infusion in hospital. In both studies the efficacy, safety and mortality in the LMWH and heparin groups were similar. 28 4 2009 Low Molecular Weight Heparin Unfractionated Heparin Treatment of Venous Out of Thrombosis...

...Elaine Gray; Ana Padilla; Trevor W. Barrowcliffe Antithrombotic activities of low molecular weight heparins (LMWHs) in a venous stasis thrombosis model, when compared to unfractionated heparin (UFH), correlated better with anti-IIa activities and inhibition of thrombin generation than with anti-Xa...

...Ulrich Abildgaard Tissue factor pathway inhibitor (TFPI) is the factor Xa (FXa)-dependent coagulation inhibitor. TFPI is released to the blood after injection of heparin or low molecular weight heparin (LMWH). The post-heparin anticoagulant effect is caused by this release of TFPI. Free TFPI has...

...; Lipid Research Laboratory, VA Wadsworth Medical Center, Los Angeles, Calif., USA KeyWords Blood Chylomicron Endothelium Heart Heparan sulphate Hepatic lipase Lipoprotein lipase Liver Low molecular weight heparin Rat New Aspects on Heparin and Lipoprotein Metabolism Abstract Lipoprotein lipase (LPL...

... gynaecological surgery. The HR and MR groups were subjected to low molecular weight heparin (LMW) prophylaxis. A significant increase in plasminogen activator inhibitor type 1 (PAI-1) antigen and activity levels was observed in the HR patient group in comparison with the MR and LR groups in the preoperative...

...A.J. Palmer; W. Schramm; B. Kirchhof; R. Bergemann Low molecular weight heparin (LMWH), unfractionated heparin (UFH) and warfarin were compared with respect to efficacy and safety in the prevention of thrombo-embolism in general surgery. Meta-analysis (MA) with a priori definition of the MA...

...A.J. Palmer; K. Koppenhagen; B. Kirchhof; U. Weber; R. Bergemann The efficacy and safety of low molecular weight heparin (LMWH), unfractionated heparin (UFH) and warfarin for prophylaxis of thrombo-embolism in orthopaedic surgery were compared using meta-analysis techniques. Twenty-two studies were...

...M.H. Prins; R.G. Gelsema; A.K. Sing; L.R. van Heerde; G.J.H. den Ottolander In a group of 60 patients in the acute phase of an ischemic stroke the assumption that low-molecular-weight heparin Kabi 2165 in the dose of 2 × 2,500 anti-Xa units s.c. could prevent thromboembolic complications was tested...

.... Heparin Low molecular weight heparin Coagulation tests Factor Xa 24 07 1987 2 05 1988 24 4 2009 Haemostasis 1989;1:13-20 © 1989 S. Karger A G , Basel 0301-0147/89/0191 -0 0 13S2.75/0 Comparative Study on a New One-Stage Clotting Assay for Heparin and Its Low Molecular Weight...

...G. Janvier; G. Freyburger; S. Winnock; G. Dugrais; M. Boisseau; P. Boissiéras An open and prospective phase II trial assessing the action of a fixed dose of a low molecular weight heparin (enoxaparin), determined by the patient’s weight, in the treatment of established deep vein thrombosis...

...). The anti-Xa action of a heparin will not significantly inhibit prothrombin conversion, except in the case of ultra low molecular weight heparins (P-type heparins) that have no significant antithrombin activity. These P-type heparins need, therefore, be given at high doses to have an antithrombotic effect...

... heparin Anti-factor Xa Antithrombin Haemostasis 1990;20(suppl 1): 180-192 © 1990 S. Karger AG. Basel 0 3 0 1 - 0 14 7 /9 0 /0 2 0 7 -0 180S2.75/0 In vitro and ex vivo Activities of CY216: Comparison with Other Low Molecular Weight Heparins F.A. Ofosu Canadian Red Cross Society, Blood Transfusion...

...Christen J. Bang; Arnold Berstad; Ingebrigt Talstad The effects on primary haemostasis of unfractionated heparin and of the two low molecular weight heparins, enoxaparin and fragmin, were compared in two rat models, one employing the gastric mucosa and the other the tail skin. All three heparin...

...Ch. Doutremepuich; F. Bousquet; G.L. Gestreau; F. Toulemonde; B. Bayrou In a venous thrombosis model in the rat obtained by ligation of the inferior vena cava, the effects of standard heparin and CY 216, a low molecular weight heparin fraction, are compared. At a dosage of less than 2 mg/kg b.w. CY...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Heparin Low molecular weight heparin Heparin standardization Reference curves Monitoring heparin therapy Haemostasis 14: 205-210 (1984) © 1984 S. Karger AG, Basel 0301...

..., instructions or products referred to in the content or advertisements. Low molecular weight heparin Extracorporeal circulation Protamine sulfate, neutralization PK 10169 Haemostasis 16: 139-146 (1986) © 1986 S. Kargcr A G . Basel 0301-0147/86/0162-013952.75/0 Partial Reversal of Low Molecular...

..., instructions or products referred to in the content or advertisements. Heparin Low molecular weight heparin Renal failure Platelet factor 4 Haemostasis 16: 147-151 (1986) ©1986 S. Karger AG. Basel 0301-0147/86/0162-0147S2.75/0 Pharmacokinetic Studies of Standard Heparin and Low Molecular Weight...